ResearcherDalhousie UniversityActive in the last 2 years
Riley J. Arseneau
Matched on ORCID iD 0000-0003-1379-1211; OpenAlex author ID A5088967601. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2024: 1 paper · 2025: 2 papers · 2026: 1 paper
Papers 4
- Effective allogeneic natural killer cell therapy for pancreatic adenocarcinoma avails conserved activating receptors and evades HLA I-driven inhibition. First author DOI 10.1136/jitc-2025-013796↗
- Claudin 18 (43-14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapy. Co-author DOI 10.1016/j.tranon.2025.102362↗
- Peri-tumoural lymphocyte neighbourhoods predict longer survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2025.1730817↗
- Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. Co-author DOI 10.3390/curroncol31100461↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Thomas Arnason · 3 shared papers, 2025–2026 · strength 0.94
- Paper Effective allogeneic natural killer cell therapy for pancreatic adenocarcinoma avails conserved activating receptors an… DOI 10.1136/jitc-2025-013796↗
- Paper Claudin 18 (43-14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker … DOI 10.1016/j.tranon.2025.102362↗
- Paper Peri-tumoural lymphocyte neighbourhoods predict longer survival in pancreatic ductal adenocarcinoma. DOI 10.3389/fimmu.2025.1730817↗
- Stacey N. Lee · 3 shared papers, 2024–2026 · strength 0.83
- Paper Effective allogeneic natural killer cell therapy for pancreatic adenocarcinoma avails conserved activating receptors an… DOI 10.1136/jitc-2025-013796↗
- Paper Peri-tumoural lymphocyte neighbourhoods predict longer survival in pancreatic ductal adenocarcinoma. DOI 10.3389/fimmu.2025.1730817↗
- Paper Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. DOI 10.3390/curroncol31100461↗
- Jeanette E. Boudreau · 2 shared papers, 2025–2026 · strength 0.67
- Ravi Ramjeesingh · 3 shared papers, 2024–2025 · strength 0.67
- Paper Claudin 18 (43-14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker … DOI 10.1016/j.tranon.2025.102362↗
- Paper Peri-tumoural lymphocyte neighbourhoods predict longer survival in pancreatic ductal adenocarcinoma. DOI 10.3389/fimmu.2025.1730817↗
- Paper Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. DOI 10.3390/curroncol31100461↗
- Boris Gala-López · 3 shared papers, 2024–2025 · strength 0.67
- Paper Claudin 18 (43-14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker … DOI 10.1016/j.tranon.2025.102362↗
- Paper Peri-tumoural lymphocyte neighbourhoods predict longer survival in pancreatic ductal adenocarcinoma. DOI 10.3389/fimmu.2025.1730817↗
- Paper Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. DOI 10.3390/curroncol31100461↗
- Thomas Samson · 2 shared papers, 2025 · strength 0.51
- Carley Bekkers · 2 shared papers, 2025 · strength 0.51
- Chloe Cyr · 1 shared paper, 2024 · strength 0.16
- Masoom A. Haider · 1 shared paper, 2024 · strength 0.16
- Keith John Roberts · 1 shared paper, 2024 · strength 0.16
- Sharlene Gill · 1 shared paper, 2024 · strength 0.16
- Christina Kim · 1 shared paper, 2024 · strength 0.16
- Jessica L. Nickerson · 1 shared paper, 2024 · strength 0.16
- Sylvia S. W. Ng · 1 shared paper, 2024 · strength 0.16
- Erica S. Tsang · 1 shared paper, 2024 · strength 0.16
- George Zogopoulos · 1 shared paper, 2024 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.